BR112021005276A2 - anticorpos anti-cd45rc humanos e usos dos mesmos - Google Patents
anticorpos anti-cd45rc humanos e usos dos mesmos Download PDFInfo
- Publication number
- BR112021005276A2 BR112021005276A2 BR112021005276-3A BR112021005276A BR112021005276A2 BR 112021005276 A2 BR112021005276 A2 BR 112021005276A2 BR 112021005276 A BR112021005276 A BR 112021005276A BR 112021005276 A2 BR112021005276 A2 BR 112021005276A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- lcvr
- antibody
- binding fragment
- hcvr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306230.6A EP3626265A1 (en) | 2018-09-21 | 2018-09-21 | Anti-human cd45rc antibodies and uses thereof |
| EP18306230.6 | 2018-09-21 | ||
| PCT/EP2019/075374 WO2020058495A1 (en) | 2018-09-21 | 2019-09-20 | Anti-human cd45rc antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021005276A2 true BR112021005276A2 (pt) | 2021-07-13 |
Family
ID=63713787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021005276-3A BR112021005276A2 (pt) | 2018-09-21 | 2019-09-20 | anticorpos anti-cd45rc humanos e usos dos mesmos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12168694B2 (https=) |
| EP (2) | EP3626265A1 (https=) |
| JP (2) | JP7796531B2 (https=) |
| KR (1) | KR20210070303A (https=) |
| CN (1) | CN113164595A (https=) |
| AU (1) | AU2019343746C1 (https=) |
| BR (1) | BR112021005276A2 (https=) |
| CA (1) | CA3113562A1 (https=) |
| IL (1) | IL281608B2 (https=) |
| MX (1) | MX2021003281A (https=) |
| NZ (1) | NZ774030A (https=) |
| SG (1) | SG11202102659RA (https=) |
| WO (1) | WO2020058495A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3626265A1 (en) * | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human cd45rc antibodies and uses thereof |
| WO2021186056A1 (en) * | 2020-03-20 | 2021-09-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Chimeric antigen receptor specific for human cd45rc and uses thereof |
| PL4401842T3 (pl) | 2021-09-16 | 2025-11-24 | Aboleris Pharma | Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania |
| AU2022422572A1 (en) | 2021-12-23 | 2024-06-06 | Cimeio Therapeutics Ag | Discernible cell surface protein variants of cd45 for use in cell therapy |
| IL321599A (en) | 2022-12-23 | 2025-08-01 | Cimeio Therapeutics Ag | Antibodies targeting cd45 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| JP4942643B2 (ja) | 2004-03-02 | 2012-05-30 | シアトル ジェネティックス， インコーポレイテッド | 部分的に付加された抗体およびそれらの結合体化方法 |
| US8288352B2 (en) | 2004-11-12 | 2012-10-16 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
| JP4658125B2 (ja) | 2005-06-28 | 2011-03-23 | パイオニア株式会社 | 放送受信装置、妨害検出装置および妨害検出方法 |
| DK3248613T3 (da) | 2005-07-18 | 2022-03-14 | Seagen Inc | Beta-glucuronid-lægemiddel-linkerkonjugater |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| KR20140133958A (ko) | 2005-10-21 | 2014-11-20 | 엘에프비 유에스에이, 인크. | 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법 |
| PL2602323T3 (pl) | 2007-06-01 | 2018-06-29 | Open Monoclonal Technology, Inc. | Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego |
| US20120258496A1 (en) | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
| FR3003171B1 (fr) | 2013-03-15 | 2015-04-10 | Lab Francais Du Fractionnement | Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire |
| US20170226209A1 (en) * | 2014-08-01 | 2017-08-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An anti-cd45rc antibody for use as drug |
| GB201601073D0 (en) * | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
| EP3626265A1 (en) * | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human cd45rc antibodies and uses thereof |
-
2018
- 2018-09-21 EP EP18306230.6A patent/EP3626265A1/en not_active Withdrawn
-
2019
- 2019-09-20 SG SG11202102659RA patent/SG11202102659RA/en unknown
- 2019-09-20 US US17/277,511 patent/US12168694B2/en active Active
- 2019-09-20 BR BR112021005276-3A patent/BR112021005276A2/pt unknown
- 2019-09-20 NZ NZ774030A patent/NZ774030A/en unknown
- 2019-09-20 CN CN201980076451.4A patent/CN113164595A/zh active Pending
- 2019-09-20 MX MX2021003281A patent/MX2021003281A/es unknown
- 2019-09-20 IL IL281608A patent/IL281608B2/en unknown
- 2019-09-20 AU AU2019343746A patent/AU2019343746C1/en active Active
- 2019-09-20 KR KR1020217011256A patent/KR20210070303A/ko not_active Ceased
- 2019-09-20 CA CA3113562A patent/CA3113562A1/en active Pending
- 2019-09-20 WO PCT/EP2019/075374 patent/WO2020058495A1/en not_active Ceased
- 2019-09-20 EP EP19778452.3A patent/EP3852802A1/en active Pending
- 2019-09-20 JP JP2021516406A patent/JP7796531B2/ja active Active
-
2024
- 2024-11-01 US US18/934,376 patent/US20250122300A1/en active Pending
-
2025
- 2025-07-25 JP JP2025124669A patent/JP2025164963A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019343746A1 (en) | 2021-04-15 |
| US20220033500A1 (en) | 2022-02-03 |
| EP3852802A1 (en) | 2021-07-28 |
| JP7796531B2 (ja) | 2026-01-09 |
| JP2022502024A (ja) | 2022-01-11 |
| CA3113562A1 (en) | 2020-03-26 |
| WO2020058495A1 (en) | 2020-03-26 |
| CN113164595A (zh) | 2021-07-23 |
| MX2021003281A (es) | 2021-08-11 |
| AU2019343746C1 (en) | 2026-04-02 |
| US20250122300A1 (en) | 2025-04-17 |
| SG11202102659RA (en) | 2021-04-29 |
| JP2025164963A (ja) | 2025-10-31 |
| AU2019343746B2 (en) | 2025-12-04 |
| EP3626265A1 (en) | 2020-03-25 |
| IL281608A (en) | 2021-05-31 |
| IL281608B1 (en) | 2025-12-01 |
| IL281608B2 (en) | 2026-04-01 |
| US12168694B2 (en) | 2024-12-17 |
| KR20210070303A (ko) | 2021-06-14 |
| NZ774030A (en) | 2026-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250122300A1 (en) | Anti-human cd45rc antibodies and uses thereof | |
| TWI674274B (zh) | 抗體－飛諾莫接合物 | |
| ES2765874T3 (es) | Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios | |
| JP2021151253A (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 | |
| JP7796034B2 (ja) | ヒトｃｄ４５ｒｃに特異的なキメラ抗原受容体およびその使用 | |
| JP7562058B2 (ja) | 抗ｃｄ４５ｒｃ抗体を用いる単一遺伝子疾患の処置 | |
| CN115515615A (zh) | Pilra抗体及其使用方法 | |
| TW202134286A (zh) | 抗ｇｐｃ３抗體、其抗原結合片段及其醫藥用途 | |
| ES2695151T3 (es) | Agentes de ligación a TLR3 | |
| JP2024503724A (ja) | 免疫調節抗体およびその使用 | |
| US20250313631A1 (en) | Treatment and prevention of cancer using vista antigen-binding molecules | |
| BR112021014574A2 (pt) | Competidores cd31 e usos dos mesmos | |
| EP4393949A1 (en) | Pharmaceutical composition containing fusion protein | |
| TW202216198A (zh) | 使用抗組織因子抗體之炎性疾病治療 | |
| RU2826421C2 (ru) | Выделенное антитело к CD45RC человека, нуклеиновая кислота, вектор экспрессии, клетка, фармацевтическая композиция, их применение, in vitro способ обнаружения hCD45RC | |
| ES2718226T3 (es) | Accionador telescópico lineal | |
| CN114591428B (zh) | 抗Dsg1抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES (FR) ; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; NANTES UNIVERSITE (FR) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |